Shilpa Medicare Limited (BOM: 530549)
India
· Delayed Price · Currency is INR
872.90
+48.15 (5.84%)
At close: Nov 14, 2024
Shilpa Medicare Revenue
Shilpa Medicare had revenue of 2.93B INR in the quarter ending June 30, 2024, with 12.43% growth. This brings the company's revenue in the last twelve months to 11.84B, up 12.85% year-over-year. In the fiscal year ending March 31, 2024, Shilpa Medicare had annual revenue of 11.53B with 9.64% growth.
Revenue (ttm)
11.84B
Revenue Growth
+12.85%
P/S Ratio
3.11
Revenue / Employee
12.18M
Employees
1,007
Market Cap
75.77B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 11.53B | 1.01B | 9.64% |
Mar 31, 2023 | 10.52B | -952.56M | -8.31% |
Mar 31, 2022 | 11.47B | 2.45B | 27.21% |
Mar 31, 2021 | 9.02B | -66.41M | -0.73% |
Mar 31, 2020 | 9.08B | 1.75B | 23.79% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionShilpa Medicare News
- 4 weeks ago - Shilpa Medicare shares jump 3% as CDMO customer secures USFDA Fast Track Designation for GBM Drug - Business Upturn
- 6 weeks ago - Shilpa Medicare shares surge over 2% after arm gets CEP from EDQM for Desmopressin - Business Upturn
- 6 weeks ago - Shilpa Pharma Lifesciences receives CEP for Desmopressin from EDQM - Business Upturn
- 6 weeks ago - Shilpa Pharma Lifesciences gets certificate of suitability from EDQM for API, Desmopressin - Business Upturn
- 2 months ago - Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as new CEO - Business Upturn
- 2 months ago - Shilpa Medicare shares rise 4% to after Antique initiates ‘Buy’ rating with target price of ₹1300 - Business Upturn
- 2 months ago - Shilpa Medicare Stock: Share price surges 9% this week on USFDA approval for Bortezomib Injection - Business Upturn
- 2 months ago - Shilpa Medicare surges over 5% on USFDA approval for Bortezomib Injection - Business Upturn